Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. - Wikidata - awgldk - TriplyDB

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.

http://www.wikidata.org/entity/Q44486379

about

Computerized advice on drug dosage to improve prescribing practice Therapeutic drug monitoring of antiretrovirals for people with HIV Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy.Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study.Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Individualization of antiretroviral therapy.Gender: a possible determinant in dosing of dermatologic drugs--an overview.Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings.Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.Pharmacologic consideration for the use of antiretroviral agents in the elderly.Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Pharmacogenomics of CYP3A: considerations for HIV treatment.Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.Therapeutic drug monitoring in highly active antiretroviral therapy.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.A Prospective Study of Adherence and Virologic Failure in HIV-Infected Patients: Role of a Single Determination of Plasma Levels of Antiretroviral Medications.Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.Minimum effective plasma concentration of efavirenz in treatment-naïve Chinese HIV-infected patients.Monitoring therapy.Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir).Usefulness of therapeutic drug monitoring of antiretrovirals in routine clinical practice.

P2860

Q24202497-D209AAED-5B9E-42C0-98EE-12CD3669ACD7 Q24239932-5FA6610C-B430-4E1E-911A-840564DDF342 Q33622168-923EE133-AF6D-461B-8466-62601683B02C Q33681426-130F3FD0-674B-4F15-AFB5-F2DCEBB2683A Q33765130-BB18580C-091F-4281-9C47-6D242A428E88 Q33802781-CECE2850-7186-4951-9772-FCF36FA2A965 Q34103495-BBECC54E-6D8F-4BDA-944C-160D741C9FA1 Q34351993-7F3ACE13-6C48-429F-95E7-AA800F343FEA Q34754376-87624358-3BEE-4B48-9060-469FBEEB0136 Q35023687-F73CF21F-4335-47E3-BAFB-9A743FC41DF3 Q35061983-239949AC-2815-4F50-9CB8-80293E730276 Q35826765-4DB1B379-7A7F-4A30-98A2-D09F873CD20A Q35826795-99B3E5F1-3918-4B50-8316-43F30633C2CC Q35826943-43B6F09A-0F91-4C2A-A8C4-4568EDE72AB5 Q35827743-3973663A-6F33-45E8-83A0-45B1D61C412E Q35827870-D8F6AEF0-4FA6-4FC6-9544-D5E3C6314D3D Q35894312-4507C3EC-6466-4D25-ACE3-7EB238D3B49C Q35898538-1A82B3C6-3A16-40D8-8BD1-30B9F4B6D6B8 Q36024483-EB3C5B0E-C6FD-413F-95D7-41FF2D45A2DC Q36376533-D14A6C3D-B817-48E3-BE30-89BD82C2751E Q36441423-9E0135D9-AE60-49A3-A26B-B22C255E66B8 Q36596188-8C46AFA6-76FB-43FE-9204-18E8D4B2F79B Q36667227-ABC25D8D-0C23-403D-943D-B88732C84137 Q36803454-BF1F5660-CBE4-4BC8-9203-B799651017D6 Q36835807-79B56BAF-034F-4691-B2BB-B1D79498C171 Q36870884-17C70709-86E0-4D63-8984-F79978D68A90 Q37277510-5C6EE574-AC5B-48BC-B11C-ED6C14F3DBE1 Q37298637-AED31B93-8D93-4DE6-9FD6-F798A1D2D107 Q37378110-64EAA5B2-6EA0-44B7-AB0D-AF0DB1165CDC Q37419542-8FD89671-1943-4AB8-928E-ED6B0D800730 Q37489345-DD72A891-F7F0-47E8-9362-D5ABBB0DDB79 Q37598636-E8A7EC69-FB1A-4DEF-B681-3BA4B2BD401C Q37720765-5BE61B02-6264-4212-850F-76B01E4A655A Q38954109-097677A6-5087-4938-BEA4-8E6C1AB591E7 Q40173631-6259A03A-9EA3-4D4D-BE8D-9BE167FCA669 Q40219167-589302EE-9205-4708-8245-604195052DB9 Q42752406-19D2BFEC-369E-406E-927F-E50151249233 Q42759049-84A947E2-76E4-4C20-AB69-26F11514A9FD Q43185204-8CEF2058-3F2E-412E-B8C2-1A4C78A42179 Q43469365-19913276-1405-4D61-A896-60A990939185

P2860

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.

http://www.wikidata.org/entity/Q44486379

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Therapeutic drug monitoring of ...... ve HIV-1-infected individuals.

@en

Therapeutic drug monitoring of ...... ve HIV-1-infected individuals.

@nl

type

label

Therapeutic drug monitoring of ...... ve HIV-1-infected individuals.

@en

Therapeutic drug monitoring of ...... ve HIV-1-infected individuals.

@nl

prefLabel

Therapeutic drug monitoring of ...... ve HIV-1-infected individuals.

@en

Therapeutic drug monitoring of ...... ve HIV-1-infected individuals.

@nl

P1433

Q44486379-508DA2D5-B42B-4FB3-952E-CC455D684785

P1476

Q44486379-AD3E5A6B-BE62-4A10-B236-076DEEE156AB

P2093

Q44486379-07363A31-C198-45EC-851D-E18CE5A3084A

Q44486379-1444A881-9D4D-45C6-B6B4-8C90B7FE1674

Q44486379-1F666A4B-26FA-456C-857B-7F0ACB3E4AD1

Q44486379-2F0B2D9E-1021-452B-8601-ADAC3E17F7AB

Q44486379-40ADF3BB-A4B1-4179-BED9-3A5015141DF7

Q44486379-5F9354DB-3DEB-48C1-8243-2F99737E659F

Q44486379-82DE2444-E76A-4FFF-B5B9-6B8D00A715D7

Q44486379-83DA6C11-FCC2-4D2B-88F0-56F8472C9235

Q44486379-91874456-86DE-4D69-B650-2EB2A1D55C6D

Q44486379-B4DB5AAA-944B-4C90-BEA7-C0932B5D0987

P304

Q44486379-0DEDC27F-BD36-4579-80D7-6CC023EC342F

P31

Q44486379-D5FBC88C-240F-4829-B684-68A659739BAC

P356

Q44486379-240BBEB1-3A61-4E31-8FED-F855EE8F4F9C

P407

Q44486379-0C571153-09FA-42D6-8AC1-6D64816C7CF6

P433

Q44486379-6F3E964C-05A5-4936-9D40-F153AD029468

P478

Q44486379-5CB8CC8C-EBAB-45B1-81B2-FE3B3CB83C46

P577

Q44486379-B5BE6AC1-FBBE-497A-962B-6312BAF9290C

P698

Q44486379-DA0FF251-89AF-428F-9318-788A616A8A4C

P356

00002030-200305230-00007

P1433

P1476

Therapeutic drug monitoring of ...... ve HIV-1-infected individuals.

@en

P2093

ATHENA Cohort Study Group

http://www.w3.org/2001/XMLSchema#string

Clemens Richter

http://www.w3.org/2001/XMLSchema#string

David Burger

http://www.w3.org/2001/XMLSchema#string

Frank Kroon

http://www.w3.org/2001/XMLSchema#string

Gerrit Schreij

http://www.w3.org/2001/XMLSchema#string

Inge Gyssens

http://www.w3.org/2001/XMLSchema#string

Jan Prins

http://www.w3.org/2001/XMLSchema#string

Joep Lange

http://www.w3.org/2001/XMLSchema#string

Kees Brinkman

http://www.w3.org/2001/XMLSchema#string

Margriet Schneider

http://www.w3.org/2001/XMLSchema#string

P304

1157-1165

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00002030-200305230-00007

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12819517

http://www.w3.org/2001/XMLSchema#string